Sarilumab Biosimilar - Research Grade

Human

IL-6R

>1mg/ml

Human IgG1 (E356D/M358L)-kappa

Tocilizumab Biosimilar - Research Grade (ICH4012), Satralizumab Biosimilar - Research Grade (ICH5106), Levilimab Biosimilar - Research Grade (ICH5639)

https://www.imgt.org/mAb-DB/

ICH3002

P08887

Blue ice

This is a research-grade, unconjugated non-therapeutic recombinant analog of sarilumab, an anti-interleukin-6 receptor (IL-6R) monoclonal antibody. It is built as a human IgG1-kappa immunoglobulin (with the E356D/M358L allotype substitutions noted on the card) that reproduces the antigen-binding specificity of the originator drug against the human IL-6 receptor alpha subunit. It is intended strictly for research use only (RUO) and is not the clinical product; it is not for human or veterinary use. The format is useful in the lab as a well-defined, reproducible IL-6R-directed binder for a range of applications: as a positive or isotype-matched reference control, for characterizing IL-6R expression and blockade, for in-vitro neutralization and receptor-competition assays, for biosimilarity and analytical comparability work, and as a benchmark tool in antibody-engineering and assay-development pipelines. It is supplied with low endotoxin (research grade typically less than 1 EU/mg, ultra-low grade less than 0.5 EU/mg) and can be produced at bulk milligram-to-gram scale to support screening, standard curves, and preclinical model work where a consistent, characterized reagent is required. Interleukin-6 receptor alpha (IL-6R, IL-6Ralpha, CD126; UniProt P08887) is the ligand-binding subunit of the IL-6 receptor system. IL-6 first binds IL-6R and this complex then recruits two molecules of the signal-transducing subunit gp130 (IL-6ST/CD130), triggering JAK-mediated activation of STAT3 (and STAT1) as well as SHP2/Ras-MAPK and PI3K pathways. IL-6R exists in a membrane-bound form on hepatocytes and leukocytes (classic signaling) and as a soluble ectodomain (sIL-6R) generated by ADAM17-mediated shedding or alternative splicing; soluble IL-6R enables trans-signaling on cells that express gp130 but little membrane IL-6R, broadening IL-6 responsiveness. This axis drives the hepatic acute-phase response, B- and T-cell responses, and Th17 differentiation, and is a central node in inflammatory and autoimmune disease. Blocking IL-6R inhibits both classic and trans-signaling.

IL-6 receptor subunit alpha, IL-6R subunit alpha, IL-6R-alpha, IL-6RA, IL-6R 1, Membrane glycoprotein 80, gp80, Interleukin-6 receptor subunit alpha

Detects human IL-6R

This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

Q: Is the Sarilumab biosimilar available in gram quantities?

A: Yes — it is supplied in scalable milligram to gram quantities for heavy-usage and high-throughput laboratories.

Q: Is this research-grade Sarilumab biosimilar suitable for in vivo studies?

A: Yes, it is a low-endotoxin, in vivo-ready formulation intended for preclinical and in vivo research use only (RUO).

Q: What does the Sarilumab biosimilar target?

A: It is an unconjugated, non-therapeutic analog of Sarilumab that binds human IL-6R.